Literature DB >> 33368820

Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real-world trials.

Gema Requena1, Achim Wolf2, Rachael Williams2, Daniel Dedman2, Jennifer K Quint3, Tarita Murray-Thomas2, Jeanne M Pimenta1.   

Abstract

PURPOSE: To assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial.
METHODS: A retrospective multidatabase cohort study using CPRD primary care and linked secondary care data to describe the characteristics of populations of patients with COPD. Patients' demographic and lifestyle factors, comorbidity profile, spirometry measurements and treatment changes were evaluated, as was the distribution of follow-up time and types of losses during follow-up. Characteristics were evaluated using descriptive statistics.
RESULTS: A total of 322 991 patients from 1148 primary care practices in the United Kingdom across two CPRD primary care databases, CPRD GOLD and CPRD Aurum, were potentially eligible to participate in a hypothetical trial using CPRD, starting on 31 December 2017. Patients with COPD in CPRD GOLD and CPRD Aurum were comparable in terms of age (median age 70 vs. 68 years), gender (50% vs. 52% male), disease severity (e.g., 25% vs. 24% Medical Research Council [MRC] dyspnoea score grades 3-5) and history of respiratory conditions (e.g., 43% vs. 38% asthma). High proportions of patients with COPD in CPRD GOLD and CPRD Aurum were available on 31 December 2012 for follow-up at 1, 2, and 5 years (92%, 85% and 67%, respectively).
CONCLUSIONS: Patients and data from CPRD GOLD and CPRD Aurum were comparable across key aspects relevant to COPD trials. A pragmatic trial using CPRD to recruit patients with COPD is scientifically feasible.
© 2020 GSK. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.

Entities:  

Keywords:  chronic obstructive pulmonary disease; electronic health record; feasibility studies; general practice; primary health care; real world clinical trials

Year:  2021        PMID: 33368820      PMCID: PMC7986187          DOI: 10.1002/pds.5188

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  19 in total

1.  Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

Authors:  Louis P Garrison; Peter J Neumann; Pennifer Erickson; Deborah Marshall; C Daniel Mullins
Journal:  Value Health       Date:  2007 Sep-Oct       Impact factor: 5.725

2.  Series: Pragmatic trials and real world evidence: Paper 8. Data collection and management.

Authors:  Anna-Katharina Meinecke; Paco Welsing; George Kafatos; Des Burke; Sven Trelle; Maria Kubin; Gaelle Nachbaur; Matthias Egger; Mira Zuidgeest
Journal:  J Clin Epidemiol       Date:  2017-07-14       Impact factor: 6.437

3.  Spatial distribution of clinical computer systems in primary care in England in 2016 and implications for primary care electronic medical record databases: a cross-sectional population study.

Authors:  Evangelos Kontopantelis; Richard John Stevens; Peter J Helms; Duncan Edwards; Tim Doran; Darren M Ashcroft
Journal:  BMJ Open       Date:  2018-02-28       Impact factor: 2.692

4.  Recruitment of patients with Chronic Obstructive Pulmonary Disease (COPD) from the Clinical Practice Research Datalink (CPRD) for research.

Authors:  Jennifer K Quint; Elisabeth Moore; Adam Lewis; Maimoona Hashmi; Kirin Sultana; Mark Wright; Liam Smeeth; Lia Chatzidiakou; Roderic Jones; Sean Beevers; Sefki Kolozali; Frank Kelly; Benjamin Barratt
Journal:  NPJ Prim Care Respir Med       Date:  2018-06-19       Impact factor: 2.871

5.  Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort Study.

Authors:  Daniel Dedman; Sonia J Coton; Rebecca E Ghosh; Wilhelmine Meeraus; Courtney Crim; Catherine Harvey; Justyna Amelio; Sarah H Landis
Journal:  Pulm Ther       Date:  2019-04-24

6.  Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real-world trials.

Authors:  Gema Requena; Achim Wolf; Rachael Williams; Daniel Dedman; Jennifer K Quint; Tarita Murray-Thomas; Jeanne M Pimenta
Journal:  Pharmacoepidemiol Drug Saf       Date:  2021-01-09       Impact factor: 2.890

7.  The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials.

Authors:  Tjeerd-Pieter van Staa; Lisa Dyson; Gerard McCann; Shivani Padmanabhan; Rabah Belatri; Ben Goldacre; Jackie Cassell; Munir Pirmohamed; David Torgerson; Sarah Ronaldson; Joy Adamson; Adel Taweel; Brendan Delaney; Samhar Mahmood; Simona Baracaia; Thomas Round; Robin Fox; Tommy Hunter; Martin Gulliford; Liam Smeeth
Journal:  Health Technol Assess       Date:  2014-07       Impact factor: 4.014

8.  Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD).

Authors:  Jennifer K Quint; Hana Müllerova; Rachael L DiSantostefano; Harriet Forbes; Susan Eaton; John R Hurst; Kourtney Davis; Liam Smeeth
Journal:  BMJ Open       Date:  2014-07-23       Impact factor: 2.692

Review 9.  Innovation at the Intersection of Clinical Trials and Real-World Data Science to Advance Patient Care.

Authors:  Brandon Swift; Lokesh Jain; Craig White; Vasu Chandrasekaran; Aman Bhandari; Dyfrig A Hughes; Pravin R Jadhav
Journal:  Clin Transl Sci       Date:  2018-05-16       Impact factor: 4.689

Review 10.  Disruptive and avoidable: GDPR challenges to secondary research uses of data.

Authors:  David Peloquin; Michael DiMaio; Barbara Bierer; Mark Barnes
Journal:  Eur J Hum Genet       Date:  2020-03-02       Impact factor: 5.351

View more
  2 in total

1.  Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real-world trials.

Authors:  Gema Requena; Achim Wolf; Rachael Williams; Daniel Dedman; Jennifer K Quint; Tarita Murray-Thomas; Jeanne M Pimenta
Journal:  Pharmacoepidemiol Drug Saf       Date:  2021-01-09       Impact factor: 2.890

2.  Trends in the Annual Consultation Incidence and Prevalence of Low Back Pain and Osteoarthritis in England from 2000 to 2019: Comparative Estimates from Two Clinical Practice Databases.

Authors:  Dahai Yu; Matthew Missen; Kelvin P Jordan; John J Edwards; James Bailey; Ross Wilkie; Justine Fitzpatrick; Nuzhat Ali; Paul Niblett; George Peat
Journal:  Clin Epidemiol       Date:  2022-02-17       Impact factor: 4.790

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.